Ritlecitinib approved for alopecia areata, largest JAK inhibitor trial confirms 80% regrowthStemson Therapeutics completes first human follicle cloning safety studyExosome therapy: 18-month follow-up data shows durable results in 62% of patientsCRISPR-based AGA treatment enters Phase I, first gene-editing approach for hair lossClascoterone Phase 3 results: topical antiandrogen matches finasteride without systemic effectsOral minoxidil 1.25mg outperforms topical 5% in new randomised trialWnt pathway activator SM04554 fails Phase III, researchers identify whyScalp microbiome transplant: first human results show promise for seborrheic alopeciaPRP meta-analysis 2025: 28 trials, 1,400 patients, here are the real numbersDutasteride mesotherapy significantly outperforms oral dutasteride in crown hair densityRitlecitinib approved for alopecia areata, largest JAK inhibitor trial confirms 80% regrowthStemson Therapeutics completes first human follicle cloning safety studyExosome therapy: 18-month follow-up data shows durable results in 62% of patientsCRISPR-based AGA treatment enters Phase I, first gene-editing approach for hair lossClascoterone Phase 3 results: topical antiandrogen matches finasteride without systemic effectsOral minoxidil 1.25mg outperforms topical 5% in new randomised trialWnt pathway activator SM04554 fails Phase III, researchers identify whyScalp microbiome transplant: first human results show promise for seborrheic alopeciaPRP meta-analysis 2025: 28 trials, 1,400 patients, here are the real numbersDutasteride mesotherapy significantly outperforms oral dutasteride in crown hair density

The science of hair loss, decoded.

Daily research coverage tracking credible treatments, trials, and emerging hair loss science.

Cure deadline

1233d16h58m20s

One breakthrough a day, every day

Don’t miss the cure announcement.

Join readers who track every study, every trial, every step toward 2030.

Free forever. No spam. Unsubscribe anytime. See our privacy policy.